Clofibride - Misplaced Pages

This is an old revision of this page, as edited by CheMoBot (talk | contribs) at 08:19, 1 September 2011 (Updating {{drugbox}} (changes to watched fields - added verified revid - updated 'ChEMBL_Ref', 'ChEBI_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report errors or [[user talk:CheMoBot|b). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Revision as of 08:19, 1 September 2011 by CheMoBot (talk | contribs) (Updating {{drugbox}} (changes to watched fields - added verified revid - updated 'ChEMBL_Ref', 'ChEBI_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report errors or [[user talk:CheMoBot|b)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound

Clofibride
Clinical data

ATC code	C10AB10 (WHO)
Pharmacokinetic data
Metabolism	Hydrolyzed to clofibric acid; hepatic glucuronidation
Elimination half-life	12 hours (clofibric acid)
Excretion	Renal (mostly) and fecal
Identifiers
IUPAC name 3-(dimethylcarbamoyl)propyl 2-(4-chlorophenoxy)-2-methylpropanoate
CAS Number	26717-47-5
PubChem CID	160134
ChemSpider	140758
UNII	0S9SLS3L93
KEGG	D07188
CompTox Dashboard (EPA)	DTXSID1022841
ECHA InfoCard	100.043.542
Chemical and physical data
Formula	C₁₆H₂₂ClNO₄
Molar mass	327.803 g/mol g·mol
3D model (JSmol)	Interactive image
SMILES Clc1ccc(OC(C(=O)OCCCC(=O)N(C)C)(C)C)cc1
InChI InChI=1S/C16H22ClNO4/c1-16(2,22-13-9-7-12(17)8-10-13)15(20)21-11-5-6-14(19)18(3)4/h7-10H,5-6,11H2,1-4H3 Key:CXQGFLBVUNUQIA-UHFFFAOYSA-N
(verify)

Clofibride is a fibrate.

Lipid-lowering agents (C10)

GI tract

Cholesterol absorption inhibitors, NPC1L1	Ezetimibe Hyzetimibe SCH-48461
Bile acid sequestrants/resins (LDL)	Colesevelam Colestilan Colestipol Colestyramine Colextran Soluble fiber such as psyllium and glucomannan

Liver

Statins (HMG-CoA reductase, LDL)	Atorvastatin Cerivastatin Fluvastatin Lovastatin Mevastatin Pitavastatin Pravastatin Rosuvastatin Simvastatin
Niacin and derivatives (HDL and LDL)	Acipimox Aluminium nicotinate Niacin Niceritrol Nicofuranose Nicotinyl alcohol
MTTP inhibitors (VLDL)	Dirlotapide Lomitapide Mitratapide
ATP citrate lyase inhibitors (LDL)	Bempedoic acid
Thyromimetics (VLDL)	Dextrothyroxine Resmetirom

Blood vessels

PPAR agonists (LDL)

Fibrates	Aluminium clofibrate Bezafibrate Choline fenofibrate Ciprofibrate Clinofibrate Clofibrate Clofibride Etofibrate Fenofibrate Gemfibrozil Nafenopin Pemafibrate Ronifibrate Simfibrate
Others	GW501516

CETP inhibitors (HDL)

PCSK9 inhibitors (LDL)

ANGPTL3 inhibitors (LDL/HDL)

Evinacumab

Combinations

Other

WHO-EM
Withdrawn from market
Clinical trials:
- Phase III
- Never to phase III

This drug article relating to the cardiovascular system is a stub. You can help Misplaced Pages by expanding it.

Categories: